{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-chronic/goals-outcome-measures/qipp-options-for-local-implementation/","result":{"pageContext":{"chapter":{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation","depth":2,"htmlHeader":"<!-- begin field a85b54ad-57c0-4007-8060-c5cadb1b2259 --><h2>QIPP - Options for local implementation</h2><!-- end field a85b54ad-57c0-4007-8060-c5cadb1b2259 -->","summary":null,"htmlStringContent":"<!-- begin item f20eee7f-cc27-4b9b-961d-d39c46fbaae5 --><!-- begin field 79db6bff-87d9-4270-b959-74c8f67a9d66 --><ul><li><strong>Non-steroidal anti-inflammatory drugs (NSAIDs)</strong><ul><li>Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (for example, older patients).</li><li>If an NSAID is needed, use ibuprofen (1,200 mg a day or less) or naproxen (1,000 mg a day or less). Use the lowest effective dose and the shortest duration of treatment necessary to control symptoms.</li><li>Co-prescribe a proton pump inhibitor (PPI) with NSAIDs for people with osteoarthritis, rheumatoid arthritis, and think about the use of gastroprotective treatment when prescribing NSAIDs for low back pain, axial spondyloarthritis, psoriatic arthritis and other peripheral spondyloarthritides.</li></ul></li><li><strong>Antimicrobial stewardship: prescribing antibiotics</strong><ul><li>Review and, if appropriate, revise local policies that relate to antimicrobial stewardship to ensure these are in line with NICE guidelines on <a href=\"https://www.nice.org.uk/guidance/ng15\" data-hyperlink-id=\"8e9182bd-2f0b-461f-8cd0-aac6008d38db\">antimicrobial stewardship: systems and processes for effective antimicrobial medicine use</a> and a<a href=\"https://www.nice.org.uk/guidance/ng63\" data-hyperlink-id=\"7d37cc76-c1e5-4a23-8352-aac6008d391b\">ntimicrobial stewardship: changing risk-related behaviours in the general population</a>.</li><li>Optimise current prescribing practice and use implementation techniques to ensure prescribing is in line with NICE <a href=\"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/antimicrobial-prescribing-guidelines\" data-hyperlink-id=\"1aed24c3-ac34-4383-84c4-aac6008d3930\">antimicrobial prescribing guidelines</a> or PHE guidance on <a href=\"https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care\" data-hyperlink-id=\"d19d6214-8492-4c16-a638-aac6008d3945\">managing common infections in primary care</a>, PHE guidance <a href=\"https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus\" data-hyperlink-id=\"5d908bd6-c001-474b-8a69-aac6008d3973\">Start smart − then focus</a>, local trust antimicrobial guidelines and the Antimicrobial Stewardship in Primary Care collaboration <a href=\"https://www.rcgp.org.uk/TARGETantibiotics\" data-hyperlink-id=\"bb2c5a36-1668-4fa9-8564-aac6008d3981\">TARGET antibiotics toolkit</a>.</li><li>Promote the <a href=\"https://antibioticguardian.com/\" data-hyperlink-id=\"e209d62c-4d1a-4160-baf6-aac6008d3a1f\">Antibiotic Guardian</a> call to action and the <a href=\"https://campaignresources.phe.gov.uk/resources/campaigns/58-keep-antibiotics-working\" data-hyperlink-id=\"427ec741-3a5d-44eb-9420-aac6008d3aed\">Keep Antibiotics Working campaign</a>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">NICE, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">NICE, 2019</a>] </p><!-- end field 79db6bff-87d9-4270-b959-74c8f67a9d66 --><!-- end item f20eee7f-cc27-4b9b-961d-d39c46fbaae5 -->","topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","lastRevised":"Last revised in September 2019","chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","fullItemName":"Management","slug":"management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"71da42c9-a078-59ae-90c6-752133b53212","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}